• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Iris-claw myopic IOL shows promise during ongoing FDA trial

Article

San Francisco-In ongoing FDA clinical trial follow-up, the iris-claw myopic IOL (Artisan/Verisyse, Ophtec/AMO) continues to be associated with excellent refractive and visual outcomes along with outstanding safety and high patient satisfaction, said Elizabeth A. Davis, MD, FACS, at the American Society of Cataract and Refractive Surgery annual meeting.

Related Videos
Related Content
Phoenix-Micron Inc and ArtiKode Intelligence team up to enhance OCT imaging with AI

Phoenix-Micron Inc and ArtiKode Intelligence team up to enhance OCT imaging with AI

Article
Ehsan Sadri, MD, leads an ophthalmology innovation discussion with Jeffry Weinhuff of Visionary Ventures

(EyePod) From idea to impact: Navigating ophthalmic innovation

Podcast
Orbis, FundamentalVR team up to target training

Orbis, FundamentalVR team up to target training

Article
EyePod: Modifier Gene Therapy: What is it?

EyePod: Modifier Gene Therapy: What is it?

Podcast
ARVO flying high in Seattle

ARVO flying high in Seattle

Article
Intracortical Visual Prosthesis achieves 2 years of successful testing

Intracortical Visual Prosthesis achieves 2 years of successful testing

Article
© 2024 MJH Life Sciences

All rights reserved.